Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
All Genders
NCT07179536

Time to Ambulation After ProGlide Closure

Led by Chinese Academy of Medical Sciences, Fuwai Hospital · Updated on 2026-01-23

300

Participants Needed

1

Research Sites

25 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Transradial access has become the standard for coronary procedures due to fewer vascular complications and shorter bed rest, yet transfemoral access remains essential for complex peripheral interventions requiring larger sheaths and stronger support. Vascular closure devices (VCDs), particularly suture-mediated devices such as ProGlide, have improved femoral access by reducing hemostasis time, ambulation delay, and patient discomfort. Although early ambulation after ProGlide closure has been reported, current practice varies widely, and the relationship between ambulation timing and vascular complications remains unclear. This trial aims to evaluate the effect of different ambulation times after ProGlide closure in transfemoral peripheral angiography or intervention, with the goal of identifying the optimal time to ambulation that balances safety and efficiency.

CONDITIONS

Official Title

Time to Ambulation After ProGlide Closure

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Scheduled for peripheral angiography or endovascular intervention via transfemoral access
  • Femoral artery puncture site located at the common femoral artery
  • Use of 6-8F vascular sheath
  • Hemostasis achieved with 6F ProGlide closure device, with no active bleeding, hematoma, or limb ischemia after closure
  • Preoperative ankle-brachial index (ABI) greater than 0.9 on both sides
  • Conscious, cooperative, and with normal lower limb mobility
Not Eligible

You will not qualify if you...

  • Undergoing carotid artery intervention
  • Femoral artery diameter less than 5 mm or effective lumen less than 5 mm due to plaque
  • History of vascular complications at the puncture site
  • Abnormal heart or lung function
  • Platelet count less than 80 x 10⁹/L during procedure or use of thrombolytic agents
  • Cognitive impairment, uncooperative, or limited lower limb mobility

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Beijing Municipality, China, 100037

Actively Recruiting

Loading map...

Research Team

H

Hui Dong, MD

CONTACT

X

Xiongjing Jiang, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here